Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Goette, Andreas; Merino, José Luís; Ezekowitz, Michael D.; Zamoryakhin, Dmitry; Melino, Michael; Jin, James; Mercuri, Mlchele; Grosso, Michael; Fernández, Víctor; Al-Saady, N.; Pelekh, Natalya; Merkely, Béla; Zenin, Sergey; Kushnir, Mykola; Špinar, Jindřich; Batushkin, Valeriy; Groot, Joris R. de; Lip, Gregory Y.H.

doi:10.1016/s0140-6736(16)31474-x

Cited by 213 publications

(188 citation statements)

References 13 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…36 Unlike the X-VeRT trial, the enoxaparin lead-in resulted in better VKA treatment, allowing more patients in the VKA arm to achieve the required INR and undergo cardioversion. However, due to the low incidence of ischaemic events during cardioversion, ENSURE AF and X-VeRT trials were not statistically powered to demonstrate significance.…”

Section: Prospective Trials Investigating Direct Oral Coagulants In Pmentioning

confidence: 99%

“…36 Patients (n=2,199) were stratified according to cardioversion approach (TOE or non-TOE) and randomly assigned to receive edoxaban (n=1,095) or enoxaparin-warfarin (n=1,104).…”

Section: Prospective Trials Investigating Direct Oral Coagulants In Pmentioning

confidence: 99%

“…36 In the TOE stratum, the cardioversion procedure had to be performed within a maximum of 3 days from The next dose of edoxaban was taken the day after cardioversion and then continued daily until day 28 post-cardioversion.…”

Section: Prospective Trials Investigating Direct Oral Coagulants In Pmentioning

confidence: 99%

“…Based on the results of the ENSURE-AF study, a newly diagnosed and non-anticoagulated patient with AF could be started on edoxaban and the cardioversion procedure scheduled as early as 2 hours after the start of treatment with a TOE-guided approach, or elective cardioversion could be performed 3 weeks later without TOE, eliminating the risk to reschedule the cardioversion due to inadequate INR. 36 The use of DOACs assures that cardioversions can occur at the planned time, which is advantageous as it prevents rescheduling. An important element to stress to the patient, however, is the need for perfect adherence to medication intake (once daily in the case of edoxaban).…”

Section: Practical Advantages Offered By Direct Oral Anticoagulants Imentioning

confidence: 99%

See 3 more Smart Citations

Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation

Goette¹,

Heidbüchel

2017

Arrhythmia &Amp; Electrophysiology Review

Self Cite

View full text Add to dashboard Cite

Anticoagulation is routinely prescribed to patients with persistent AF before cardioversion to reduce the risk of thromboembolic events. As direct oral anticoagulants (DOACs) have a rapid onset of action, a consistent anticoagulant effect, if taken correctly, and do not need monitoring or dose adjustments, there is considerable interest in their use for patients with AF undergoing cardioversion. Post-hoc analyses show that DOACs are safe to use prior to and following cardioversion. In addition, two randomised controlled trials, X-VeRT and ENSURE-AF, have demonstrated the efficacy and safety of the DOACs rivaroxaban and edoxaban, respectively, in this setting. The use of DOACs allows cardioversions to be performed promptly and reduces the number of cancelled procedures compared with the use of warfarin.

show abstract

Section: Prospective Trials Investigating Direct Oral Coagulants In Pmentioning

confidence: 99%

“…36 Patients (n=2,199) were stratified according to cardioversion approach (TOE or non-TOE) and randomly assigned to receive edoxaban (n=1,095) or enoxaparin-warfarin (n=1,104).…”

Section: Prospective Trials Investigating Direct Oral Coagulants In Pmentioning

confidence: 99%

Section: Prospective Trials Investigating Direct Oral Coagulants In Pmentioning

confidence: 99%

Section: Practical Advantages Offered By Direct Oral Anticoagulants Imentioning

confidence: 99%

See 2 more Smart Citations

Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation

Goette¹,

Heidbüchel

2017

Arrhythmia &Amp; Electrophysiology Review

Self Cite

View full text Add to dashboard Cite

show abstract

“…Die rezent veröffentlichte ENSURE-AF Studie konnte zeigen, dass Edoxaban bei Patienten mit elektrischer Kardioversion eine sichere sowie effektive Alternative gegenüber einer optimalen Therapie mit NMH und VKA darstellt [48].…”

Section: Zusammenfassungunclassified

Edoxaban zur Schlaganfallprophylaxe bei Patienten mit nicht-valvulärem Vorhofflimmern und zur Behandlung venöser Thromboembolien: ein interdisziplinäres Positionspapier

Weiss

Rohla

Dieplinger

et al. 2017

Wien Med Wochenschr

View full text Add to dashboard Cite

Management of Patients With Atrial Fibrillation

Beaser

Cifu

2019

JAMA

View full text Add to dashboard Cite

Atrial fibrillation is a common arrhythmia that can be asymptomatic or disabling. Its prevalence increases with age and its presence can markedly increase the risk of stroke. Recent advances have offered new options for anticoagulation, interventions to decrease the risk of embolic stroke, and electrophysiologic approaches to convert AF back to sinus rhythm. Characteristics of the Guideline SourceThis guideline 1 was published to update the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. The ACC/AHA Task Force on Practice Guidelines invited members of the writing committee for the 2014 guidelines to update the guideline. They were joined by additional newly invited members. The group was composed of clinicians with broad expertise related to AF and its treatment. The writing group included representatives from the ACC, AHA, HRS, and the Society of Thoracic Surgeons. Members of the writing group were required to disclose all relationships with industry and those with relationships could not work on sections directly involving their relationships (Table ).

show abstract

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Cited by 213 publications

References 13 publications

Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation

Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation

Edoxaban zur Schlaganfallprophylaxe bei Patienten mit nicht-valvulärem Vorhofflimmern und zur Behandlung venöser Thromboembolien: ein interdisziplinäres Positionspapier

Management of Patients With Atrial Fibrillation

Contact Info

Product

Resources

About